Clarivate to sell Life Sciences & Healthcare business to Altaris in US$600M deal

UK—Clarivate Plc has agreed to sell its Life Sciences & Healthcare (LS&H) business to healthcare-focused investment firm Altaris LLC for US$600 million as the company sharpens its focus on its core subscription-based intelligence businesses.

The transaction marks a major step in Clarivate’s strategy to simplify its portfolio while strengthening its financial position.

Following the sale, Clarivate will concentrate on its Academia & Government (A&G) and Intellectual Property (IP) divisions.

The company said both businesses already share technology platforms, data assets and long-standing customer relationships.

It also plans to expand its AI-driven intelligence, workflow software and technology-enabled services across these two segments.

Focus shifts to core growth businesses

Chief Executive Officer Matti Shem Tov said the divestiture aligns with Clarivate’s four-pillar Value Creation Plan, which aims to optimize the company’s business model, improve sales execution, accelerate innovation and streamline its portfolio.

He said the closer alignment between the A&G and IP businesses will improve operational efficiency, strengthen innovation, and help the company reach more customers.

The move is also expected to strengthen Clarivate’s financial profile while positioning it for long-term growth in the knowledge and innovation economy.

Chief Financial Officer Jonathan Collins said that selling the LS&H unit will accelerate the company’s debt-reduction efforts.

He added that the transaction will improve Clarivate’s revenue mix, reduce capital requirements, and expand profit margins, giving the company greater flexibility to invest in future growth.

Altaris to build independent healthcare business

Henry Levy, President of Clarivate’s Life Sciences & Healthcare business, said the division combines trusted data, industry expertise and advanced analytics to support pharmaceutical and medical technology companies throughout the product lifecycle, from drug discovery to commercialization and market access.

He said the business is well positioned to grow under Altaris through continued investment and a stronger focus on customer needs.

Altaris has confirmed that the LS&H business, including the Cortellis and Decision Resources Group portfolios, will operate as an independent company after the acquisition.

The business serves about 2,500 customers worldwide, including the world’s 20 largest pharmaceutical companies.

Transaction details and financial outlook

Under the agreement, Clarivate will receive US$500 million in cash when the deal closes, US$25 million after completing a transition services agreement and a US$75 million seller note.

The company plans to use the proceeds to reduce debt and strengthen its balance sheet.

The transaction is expected to close before the end of 2026, subject to regulatory approvals and other customary closing conditions.

Clarivate also reaffirmed its full-year 2026 financial outlook.

The LS&H business will be reported as discontinued operations beginning in the third quarter.

In addition, the company expects to record a non-cash goodwill impairment of US$225 million to US$250 million related to the sale, although this will not affect its full-year financial guidance.